Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -341.90M | 317.80M | 64.00M | -715.80M | 653.20M |
| Total Depreciation and Amortization | 44.20M | 40.60M | 38.10M | 39.20M | 38.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 521.00M | -319.00M | -15.80M | 1.02B | -749.20M |
| Change in Net Operating Assets | -102.40M | 77.10M | 43.60M | -216.00M | 220.70M |
| Cash from Operations | 120.90M | 116.50M | 129.90M | 124.20M | 163.60M |
| Capital Expenditure | -31.70M | -45.70M | -34.40M | -42.91M | -40.20M |
| Sale of Property, Plant, and Equipment | 0.00 | 100.00K | -- | -49.00K | 0.00 |
| Cash Acquisitions | -1.80M | -216.70M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.50M | 146.90M | 37.30M | 12.42M | -15.50M |
| Cash from Investing | -43.00M | -115.40M | 2.90M | -30.54M | -55.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -200.00K | -100.00K | -41.00K | -100.00K |
| Issuance of Common Stock | 3.40M | 4.20M | 4.30M | 3.91M | 5.10M |
| Repurchase of Common Stock | -55.90M | -140.30M | -101.90M | -134.00K | -101.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -29.98M | 0.00 |
| Cash from Financing | -52.50M | -136.30M | -97.70M | -26.25M | -96.00M |
| Foreign Exchange rate Adjustments | 1.10M | -16.20M | -1.80M | 10.22M | -7.40M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -48.00K | -- |
| Net Change in Cash | 26.50M | -151.40M | 33.30M | 77.58M | 4.50M |